Cannabinoid

Nalu Bio and PIPA Bring Cannabinoid Combinations To CPG Brands in First-Of-Its-Kind Partnership Powered by AI

Retrieved on: 
Thursday, February 8, 2024
Partnership, Coffee, Anxiety, Traction, SAN, Vitamin, Science, AI, PIPA, Academic Medicine (journal), Clinical trial, Sleep, Pain, Safety, Food, Probiotic, Caffeine, Wellness, Chemistry, Cannabinoid, CBD, Global health, Beauty, CBN, Vitamin C, Health, Aspirin, Antioxidant, CPG, CBG, Medical device

SAN FRANCISCO, Feb. 8, 2024 /PRNewswire/ -- Nalu Bio, a biotech company specializing in no-high, chemistry-derived cannabinoids to address the top health and wellness challenges, today announced a first-of-its-kind partnership with PIPA, AI leader in Nutrition, Health and Wellness innovation to bring AI-enabled combinations of cannabinoids and bioactives to consumer packaged goods (CPG) companies. This partnership aims to create a new category of products at a time when market demand, cultural acceptance, and desire for cannabinoids are on the rise around the world.

Key Points: 
  • Nalu Bio is the first company to offer combinations of cannabinoids and bioactives to address pain, anxiety, sleep, and weight management.
  • According to Nutrition Business Journal's 2023 Supplement Report, combination sales are expected to surpass single ingredient supplement sales this year.
  • In tandem with PIPA, Nalu Bio will leverage predictive AI modeling to identify the optimal combinations of cannabinoids with unique bioactives such as vitamins, protein, fiber, antioxidants, probiotics, and superfoods.
  • Like vitamins, not only can chemically-derived cannabinoid combinations address multiple health needs, but they can scale responsibly, safely, and sustainably.

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Retrieved on: 
Thursday, February 8, 2024
Tetra, Weight gain, Cannabinoid, Public, Research, Obesity, DSM-IV codes, Schizophrenia, Patient, Intellectual property, Drug discovery, Appetite, ECS, IP, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.

Key Points: 
  • The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology.
  • COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.
  • Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain.
  • By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Retrieved on: 
Thursday, February 8, 2024
Tetra, Weight gain, Cannabinoid, Public, Research, Obesity, DSM-IV codes, Schizophrenia, Patient, Intellectual property, Drug discovery, Appetite, ECS, IP, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.

Key Points: 
  • The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology.
  • COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.
  • Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain.
  • By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.

Branded Legacy, Inc. Innovates with Launch of the First 100% Clear Kava-Based Vaping Product on the Market

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Research, Migraine, Terpene, Therapy, Sleep, Pain, Safety, Headache, Cannabinoid, Alkaloid, Pain management, Health, Legacy, Teahouse

MELBOURNE, Fla., Feb. 6, 2024 /PRNewswire/ -- Branded Legacy, Inc. (OTC.PK: BLEG), a prominent Biotech company, proudly announces a major breakthrough in research and development efforts, leading the pack on new procedures for the extraction and refinement of kavalactones. In addition, The Alcannabist LLC, a wholly owned subsidiary of Branded Legacy , announced the official release of its new line of groundbreaking products designed to address diverse health and wellness needs.

Key Points: 
  • We were able to make a high purity extract that was completely translucent and very flavorful on the first day.
  • When we presented our extract to our kava suppliers, they asked to move forward immediately with a white label contract.
  • The Alcannabist's new products, which include: VapeRx Anti Anxiety, ElixRx Migraine/Headache Support, and Mood Mix Capsules, are now officially on the market.
  • The other three, ElixRx Plus Kava Anti Anxiety, ElixRx Plus Kava Sleep, and ElixRx Plus Kava Pain Management, will be included in their ElixRx line.

Danish dog owners are medicating their pets with unlicensed cannabis products – is it safe?

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Attention, Cannabis, Cannabidiol, Chronic pain, Travel, THC, Migraine, Research, Edible, Toxicity, Lethargy, Safety, Food, Dog, Oil, Cannabinoid, Osteoarthritis, Skin, Saliva, Thought, Pain management, Vomiting, Cat, Allergy, Health, Diarrhea, Pet, Medical imaging

Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.

Key Points: 
  • Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.
  • Previous studies suggest that 80% of dog owners in the US and Canada had bought cannabis products for their pet.
  • But, is CBD safe for our pets and could it be a useful addition to our pet’s healthcare regime?
  • Indeed, 36% of respondents in the Danish study indicated that they used cannabinoids for pain management in their pets.

Linnea SA of Switzerland and Universidade Estadual de Campinas (Unicamp) Brazil announce scientific partnership to promote cannabinoids research

Retrieved on: 
Tuesday, February 6, 2024
Partnership, State University of Campinas, Active ingredient, Cannabinoid, Patient, Safety, API, Research

This important partnership aims to streamline and advance scientific development and research into cannabinoids.

Key Points: 
  • This important partnership aims to streamline and advance scientific development and research into cannabinoids.
  • Linnea SA currently sells their botanical nature derived APIs, including cannabinoids, to over 300 business partners in over 70 different countries worldwide.
  • Linnea SA is proud to promote the best practices and are strongly committed to ongoing scientific research and development through global strategic partnerships.
  • Universidade Estadual de Campinas (Unicamp) is a well respected leading research university that is responsible for around 15% of Brazilian research and also produces more patents than any other research organization in Brazil.

Premier Diversified Holdings Inc. Announces Cease Trade Order and Provides Update on the Proposed Acquisition of AJA Health and Wellness Ltd., Assured Diagnosis Inc., and AJA Therapeutics Inc.

Retrieved on: 
Monday, February 5, 2024
BCSC, MRI, News, USD, Share (finance), Medtech, ADI, Indian stock exchange, CAD, Wellness, Funding, HBO, Amalgamation, Related party transaction, Chronic pain, THC, Diagnosis, Cannabinoid, Flavonoid, LOI, Health, TSX Venture Exchange, Minority, CFO, Aspirin, AJA, Apigenin, Nonsteroidal anti-inflammatory drug, Therapy, Smartphone, Bank statement, PDH

VANCOUVER, British Columbia, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Premier Diversified Holdings Inc. ("PDH" or the "Company") (TSXV:PDH) announces that further to the press release dated January 18, 2024, whereby the Company announced the filing of an application seeking a management cease trade order (“MCTO”) from the British Columbia Securities Commission (“BCSC”) due to its inability to file its annual financial statements for the year ending September 30, 2023 including the related management’s discussion and analysis and certifications from the CEO and CFO (the “Annual Filings”), the BCSC will issue a cease trade order against PDH (the “CTO”).

Key Points: 
  • The Corporation continues to pursue the acquisitions of AJA Health and Wellness Ltd. ("AJA Health"), AJA Therapeutics Inc. ("ATI"), and Assured Diagnosis Inc. ("ADI", and together with PDH, AJA Health, and ATI, the "Parties").
  • The Acquisition, subject to certain conditions and applicable shareholder and regulatory approvals, will result in a reverse takeover of PDH.
  • There can be no assurance that the Acquisition will be completed as proposed or at all.
  • AJA Health and ADI are diligently working on having audits completed on their financial statements.

Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company

Retrieved on: 
Monday, February 5, 2024
Inflammation, DSM-IV codes, Hospital, Epidermolysis bullosa, Clinical trial, Dermatology, Cannabinoid, TSX, CBD, Ultra, CBG, Fine chemical

TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce an exclusive supply agreement for two of the Company’s proprietary topical products with a multinational pharmaceutical company (“Pharma”).

Key Points: 
  • TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce an exclusive supply agreement for two of the Company’s proprietary topical products with a multinational pharmaceutical company (“Pharma”).
  • Avicanna will be earning licensing fees associated to specific milestones and the parties have also agreed to specific minimum order quantities and efforts for Pharma to maintain the exclusivity.
  • The exclusive supply agreement is for the Company’s proprietary topical products that have been commercialized in the Canadian market under the RHO Phyto brand across several medical cannabis platforms including MyMedi.ca.
  • Additionally, the two companies have entered into a separate right of first refusal agreement related to the Company’s SEDDS technology capsules for the same region.

One World Products Confirms That Its Colombian Cannabis Operations are Unaffected by Recent Regulatory Developments in Colombia

Retrieved on: 
Monday, February 5, 2024
Cannabinoid, OWP, THC, Congress, Drug

LAS VEGAS, NV , Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Products, Inc. (the “Company,”) (OTCQB: OWPC), a fully-licensed hemp and cannabis producer in Colombia, today announced that its current business prospects are unaffected by recent regulatory and political hurdles in Colombia.

Key Points: 
  • LAS VEGAS, NV , Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Products, Inc. (the “Company,”) (OTCQB: OWPC), a fully-licensed hemp and cannabis producer in Colombia, today announced that its current business prospects are unaffected by recent regulatory and political hurdles in Colombia.
  • The Company's products, which include a range of THC solutions provided through medical channels, are derived from cannabinoids sourced from hemp and are fully compliant with current regulations.
  • Isiah Thomas, Chairman and CEO of One World Products, commented, ”Our plans remain unaltered as our products are not affected by the recent moves by Colombia’s Congress.
  • Meanwhile, a regulatory directive effective February 2024 mandates the destruction of all cannabis inventory over two years old.

Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers

Retrieved on: 
Thursday, February 1, 2024
CGMP, New Drug Application, CDMO, Society, API, DEA, Cannabinoid, Drug Enforcement Administration, Drug development, Ground substance, Schedule, Pharmaceutical industry

GAINESVILLE, Ga. and ROUND ROCK, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, and Benuvia Operations, LLC, a U.S.-based drug developer and manufacturer of active pharmaceutical ingredients (APIs) with a specialized expertise in controlled substances (cannabinoids and psychedelics), today announced the signing of a co-marketing agreement. The agreement is designed to allow the companies to promote each other’s complementary contract development and manufacturing services to their respective customer bases and new business prospects. As part of the agreement, the companies will highlight Benuvia’s specific expertise as a manufacturer of drug substance (API) and Societal’s focus on manufacturing drug product. While the agreement is not limited to any specific therapeutic indication or modality, the companies will specifically focus on leveraging their unique expertise in the area of psychedelics to address this expanding drug development market.

Key Points: 
  • The agreement is designed to allow the companies to promote each other’s complementary contract development and manufacturing services to their respective customer bases and new business prospects.
  • As part of the agreement, the companies will highlight Benuvia’s specific expertise as a manufacturer of drug substance (API) and Societal’s focus on manufacturing drug product.
  • Societal CDMO possesses a broad range of CDMO capabilities spanning formulation development, analytical testing and manufacturing of oral solid dose finished drug products.
  • Benuvia Operations, LLC, is an end-to-end CDMO with vertically integrated pharmaceutical services ranging from drug and formulation development, fully-integrated analytical services and manufacturing of oral liquid and aerosol solutions.